P3, N=480, Recruiting, DBV Technologies

The hybridoma-derived antibody mixture showed strong immunogenicity, cytokine-associated immune stimulation, and preliminary potential for breast cancer-oriented immunoassay development; however, additional validation of specificity and analytical performance is required before diagnostic utility can be concluded. The AU-565 antigen-CFA combination not only enhanced antibody production but also promoted a favorable cytokine profile, underscoring CFA's superiority as an adjuvant in breast cancer-oriented immunogen design.

Recurrent disease caused by drug-tolerant persister cells (DTPs) that evade chemotherapeutic agents (e.g., doxorubicin hydrochloride (DOX) and paclitaxel (PTX)) is a significant challenge in treating TNBC...The results revealed that pharmacological inhibition of autophagy (hydroxychloroquine) or lysosomal activity (bafilomycin A1) compromised DTPs' survival...Our results demonstrated that increased autophagy-lysosomal process renders DTP cell survival in TNBC by maintaining mitochondrial reactive oxygen species (mROS) generation, which, in turn, contributes to chemotherapy resistance. A potential treatment strategy for eradicating DTP cells and preventing tumor recurrence in TNBC involves targeting these mechanisms.

P1/2, N=12, Not yet recruiting, Cellenkos, Inc.

Additionally, some anti-inflammatory medicines suppress the development of UV-induced skin cancers. The enhancement of photosensitive medications, including voriconazole and hydrochlorothiazide on UV carcinogenesis, has been indicated both epidemiologically and experimentally.

JYD exerts therapeutic effects in SS model mice, likely by inhibiting the NF-κB signaling pathway, enhancing AQP5 protein expression, and thereby attenuating the production of proinflammatory cytokines.

P2, N=35, Recruiting, Dartmouth-Hitchcock Medical Center | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026

P1/2, N=800, Recruiting, Sanofi Pasteur, a Sanofi Company | N=260 --> 800 | Trial completion date: Aug 2028 --> Nov 2028 | Trial primary completion date: Aug 2028 --> Nov 2028

P=N/A, N=36, Recruiting, The Hospital for Sick Children | N=60 --> 36

Hydroxychloroquine (HCQ) is conditionally recommended for established autoimmune diseases or specific inflammatory placental pathologies...Maternal inflammation is a primary trigger for disturbed placentation and fetal loss. Improving outcomes for women with RPL requires a proactive, evidence-based approach that specifically targets the immunological bystander reaction pathway rather than relying on routine clotting tests.

In vivo evaluation in CT26 orthotopic colon tumor model showed enhanced tumor localization, significant tumor regression and improved survival outcomes in formulation treated group when combined with 5-fluorouracil (5-FU). Although the delayed-type hypersensitivity (DTH) assay showed a decline in % DTH response, histopathology of spleen and thymus implied enhanced lymphocyte cellularity with acute inflammatory infiltrations confirming elevated immune activation. The Mannosylated liposomal system effectively delivers immunomodulators to modulate the tumor microenvironment and enhance 5-FU based therapy in colon cancer.

P4, N=80, Not yet recruiting, University of Calgary | Trial completion date: Dec 2028 --> Dec 2030 | Trial primary completion date: Jun 2028 --> Jun 2029